The Moderna COVID-19 vaccine that Canada is set to get doses of kept antibody levels high for three months after the shot was given to people who were part of the trials.

In the New England Journal of Medicine, researchers with this vaccine candidate said that the level of antibodies slightly declined over time but still "remained elevated" three months later.

Antibodies stop the virus from getting into human cells.

Editor's Choice: Walmart Canada Is Giving All Of Its Employees An Appreciation Bonus

mRNA-1273 has the potential to provide durable humoral immunity.


Researchers said the decline was expected and the results show that the vaccine "has the potential to provide durable" immunity.

Moderna's vaccine, mRNA-1273, is two injections that are administered 28 days apart.

It was recently found to be 94.5% effective.

On December 4, Anita Anand, Minister of Public Services and Procurement, announced that Canada is now getting an additional 20 million doses of this vaccine candidate.

That will bring the total from Moderna to 40 million doses set to be delivered in 2021.

Justin Trudeau recently confirmed that Canada is guaranteed some of the first batch if the candidate is approved by Health Canada.

Comments are now closed.
Account Settings
Share Feedback
Log Out

Register this device to receive push notifications